Darolutamide: New Standard of Care in Nonmetastatic CRPC? Darolutamide: New Standard of Care in Nonmetastatic CRPC?

An investigational agent significantly extended metastasis-free survival in patients with nonmetastatic castration-resistant prostate cancer (CRPC).Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news